PAPZIMEOS Adoption and Access“Q2 represented exceptional growth from Q1,” Sabzevari said, adding that PAPZIMEOS revenue increased by more than 145% sequentially. Precigen Chief Commercial Officer Phil Tennant said the company’s patient-support hub had registered well over 500 patients as of the call. Sabzevari said Precigen expects to provide updated head and neck cancer data later this year. At June 30, Precigen had $38.7 million in cash equivalents and investments, as well as $71.9 million in trade accounts receivable. About Precigen (NASDAQ:PGEN)Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines.